3d agoInvesting.com Analyst RatingsBULLISH 56Analyst
Jefferies reiterates Compass Pathways stock rating on TRD approval confidence
Jefferies reiterates Compass Pathways stock rating on TRD approval confidence
Archived explainer. For the current picture see today's CMPS page.
Why Is COMPASS PATHWAYS ADR ADR (CMPS) Stock Up Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 12:54 PM ET · reviewed against 7 wire stories
COMPASS PATHWAYS ADR ADR (CMPS) is up +11.25% in the latest session. Our newswire has captured 7 stories on CMPS across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why CMPS stock is up today
Compass Pathways ADR (CMPS) surged 11.25% to $15.62 in early trading on Tuesday, driven by positive 52-week data from its Phase 3 COMP005 trial for treatment-resistant depression. The stock opened with a 2.2% gap up and reached a session high of $15.66 before settling near $15.60. The rally reflects growing confidence in the company’s regulatory pathway and commercial prospects for its psilocybin-based therapy COMP360.
What Happened
Compass Pathways reported topline results from Part C of its Phase 3 COMP005 trial, showing that patients who received an additional 25 mg dose of COMP360 experienced an average 13-point improvement in depression scores after 52 weeks. The open-label study also reported 40%-45% response rates and approximately 30% remission rates. These findings suggest that a second dose may extend the therapeutic benefit of COMP360 out to one year, reinforcing the durability of the treatment.
Jefferies reiterates its positive stance on the stock, citing confidence in the company’s path to TRD approval. Compass also announced a rolling FDA application is underway, with the full NDA expected in Q4 2026 and a potential U.S. launch in H1 2027 if approved. In addition, the company is preparing a U.S. healthcare provider education campaign and will present new data at the Psych Congress in September 2026.
What The Data Shows
The stock opened at $14.35 and traded in a wide range, reaching a high of $15.66. Volume so far stands at 3.0 million shares, or 0.8 times the 3-month daily average. The stock has printed two fresh 52-week lows and 21 52-week highs on September 9, 2026. CMPS is currently trading near its 52-week high of $15.40, suggesting strong near-term momentum. The stock’s beta of 2.55 indicates it is more volatile than the broader market.
What To Watch
The next key milestone for Compass Pathways is the completion of its NDA submission in Q4 2026, followed by the potential U.S. launch of COMP360 in H1 2027. Investors will also be watching for further coverage from analysts and the broader market reaction to the Phase 3 data as the stock continues to trade near its 52-week high.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CMPS by the numbers
Last: $15.62Session: +11.25%7 sessions: +14.35%Coverage: 7 stories / 4 sourcesAI sentiment: 64/100 (bullish)Mkt cap: $1.8B52w: $4.82 to $15.40
The headlines behind the move
3d agoInvesting.com Analyst RatingsBULLISH 67Product/PR
Compass Pathways stock shows durable results in depression trial
Compass Pathways stock shows durable results in depression trial
3d agoStocktwits NewsBULLISH 73Product/PR
CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch
Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks.
4d agoThe FlyBULLISH 59Product/PR
Compass Pathways reports 52-week results from Phase 3 COMP005 trial
4d agoStockTitanBULLISH 73Product/PR
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
The open-label study reported 40%-45% response and about 30% remission rates; final NDA submission is expected in Q4, with launch expected in H1 2027 if approved.
4d agoStocktwits NewsBULLISH 67Product/PR
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.
5d agoStockTitanBULLISH 56Product/PR
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Seven posters will include real-world healthcare costs, provider perspectives and 26-week COMP360 efficacy and safety data at Psych Congress Sept. 14-19.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CMPS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CMPS move explainers: 2026-09-10 · 2026-09-09 · 2026-09-08